Acquired Factor V Inhibitor Developing after Treatment with Dabigatran Etexilate Methanesulfonate: A Case Report and Review of the Literature-Reference-Cited by-同舟云学术

Acquired Factor V Inhibitor Developing after Treatment with Dabigatran Etexilate Methanesulfonate: A Case Report and Review of the Literature

Published:2014-03-06 Issue:S1 Volume:30 Page:275-279
ISSN:0971-4502
Container-title:Indian Journal of Hematology and Blood Transfusion
language:en
Short-container-title:Indian J Hematol Blood Transfus

Author:

Sekiguchi Yasunobu,Yoshikawa Hitomi,Shimada Asami,Imai Hidenori,Wakabayashi Mutsumi,Sugimoto Keiji,Nakamura Noriko,Sawada Tomohiro,Ichinose Tetsuo,Ozaki Dai,Komatsu Norio,Noguchi Masaaki

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12288-014-0358-4.pdf

Reference11 articles.

1. Ortel TL (1999) Clinical and laboratory manifestations of anti-factor V antibodies. J Lab Clin Med 133:326–334

2. Gartrell B (2011) Acquired factor V inhibitor complicating warfarin therapy. Am J Hematol 86:710–712

3. Ang AL, Kuperan P, Ng CH, Ng HJ (2009) Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 101:852–859

4. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N (2007) In-vitro profile and ex vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98:155–162

5. Horder MH (1955) Isolated factor V deficiency caused by a specific inhibitor (in German). Acta Haematol 13:235–241

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease;CEN Case Reports;2022-08-09

2. Acquired factor V inhibitor presenting as life threatening bleeding after initiation of apixaban;Haemophilia;2021-06-25

3. A rare case of acquired factor V inhibitor, during treatment with dabigatran for chronic atrial fibrillation, successfully treated with bypassing agents;Clinical Case Reports;2020-12-02

4. Successful Management of Acquired Factor V Inhibitor by Monitoring Factor V Activity, Antigen, and Inhibitor Values during Immunosuppressive Therapy;Acta Haematologica;2019-09-27

5. Acquired Factor V Inhibitor with Symptoms and Titer of Inhibitor Differences: Report of Two Cases;Acta Haematologica;2019